Healthcare Industry News: Bard
News Release - December 22, 2010
Cook Medical Releases Initial Results From Its STABLE Clinical Trial Endovascular Treatment of Aortic DissectionBLOOMINGTON, Ind.--(Healthcare Sales & Marketing Network)-- Study investigators reported positive steps in Cook Medical’s efforts to gain FDA approval of the treatment assessed in the STABLE clinical trial, designed to evaluate the safety and efficacy of a proximal endograft and a distal uncovered stent for the endovascular treatment of Type B aortic dissection for purposes of seeking FDA approval. The findings were presented by Dr. Joseph LomBardi at the 37th annual VEITHsymposium. The trial is the first and only one of its kind to focus on a device uniquely designed for the endovascular treatment of Type B aortic dissection. The system as a whole is an investigational device not available in the United States.
“The initial data for the STABLE clinical trial show promise,” said Joseph LomBardi, M.D., the study’s principal investigator and chief of vascular and endovascular surgery at Cooper University Hospital and associate professor of surgery at the Robert Wood Johnson Medical School, University of Medicine & Dentistry of New Jersey. “Aortic dissection can be a life-threatening condition, and surgical intervention is a highly invasive procedure. If confirmed, these initial results are a positive step toward proving the safety and efficacy of a minimally invasive treatment for aortic dissection.”
“We’re very pleased with the initial data, and this signifies an important step forward for Cook’s minimally invasive system for treating aortic dissection,” said Phil Nowell, vice president and global leader of Cook Medical’s Aortic Intervention strategic business unit. “Open surgery to repair dissection can take a devastating toll on a patient, and we hope the STABLE trial final results support an endovascular solution.”
Aortic dissection, the condition that took the lives of actor John Ritter and, more recently, a highly prominent U.S. diplomat, is a tear in the wall of the aorta, the major artery that carries blood out of the heart. Some dissections can be treated with blood-pressure medication, but many require open surgical intervention, which involves opening the chest cavity, clamping off the aorta and surgically implanting a graft that repairs the damaged vessel wall.
The Cook stent-graft system is comprised of two components: an endograft that seals the torn aortic section, and a second, uncovered stent that helps to support the true lumen of the aorta and promote apposition of the dissected vessel wall.
About Cook Medical
Founded in 1963, Cook Medical pioneered many of the medical devices now commonly used to perform minimally invasive medical procedures throughout the body. Today, the company integrates medical devices, drugs and biologics to enhance patient safety and improve clinical outcomes. Since its inception, Cook has operated as a family-held private corporation. For more information, visit www.cookmedical.com. Follow Cook Medical on Twitter @cookmedicalpr or @cookvascular.
Source: Cook Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.